New light on how a mutation in a protein causes acute myeloid leukaemia

An international team of scientists has shed new light on how a mutation in a protein causes acute myeloid leukaemia (AML), a type of blood cancer. The findings have implications for our understanding of AML, and the way leukaemias are treated. The work, which is partly funded by the EU, is published in the latest edition of the journal Cancer Cell.

Leukaemia is caused when a mutation occurs which allows our blood cells to divide and proliferate uncontrollably, so that defective blood cells displace the healthy blood cells. It has been known for some time that around a tenth of all AML patients have a mutation in a protein called C/EBPalpha, but until now it was unclear whether this mutation was the cause of the disease.

In this latest study, the researchers created a mouse with this mutation. Their work revealed that the mutation is indeed the cause of the disease, as it triggers genetic programmes which cause the white blood cells to proliferate uncontrollably.

The study threw up some surprises; it was once thought that myeloid leukaemia was caused by the uncontrolled proliferation of malignant blood stem cells. Instead, it now appears that this mutation acts on cells which are already turning into mature blood cells. The mutation reprogrammes these cells, causing them to proliferate and produce numerous, defective daughter cells. As these cells displace the healthy blood cells, they compromise the ability of the blood to transport oxygen around the body.

"This is the first time that non-stem cell myeloid leukaemia has been generated within a healthy blood system," commented Claus Nerlov of the European Molecular Biology Laboratory's Mouse Biology Unit in Monterotondo, Italy. "The findings will have profound implications for our understanding of the development and treatment of leukaemias."

The scientists identified a genetic programme which was triggered by the mutation and found that it is similar to the programme triggered by other mutations linked to other leukaemias. Currently, efforts to develop anti-leukaemia drugs are focused on these mutations, but the new findings suggest that it could be better to focus on the genetic pathways which are shared by many different cancer stem cells.

EU support for the work came from the EuroCSC ('Targeting cancer stem cells for therapy') project, which is funded under the 'Life sciences, genomics and biotechnology for health' thematic area of the Sixth Framework Programme (FP6).

For more information, please visit:
http://www.embl.org
http://www.cancercell.org

Copyright ©European Communities, 2008
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Pfizer and BioNTech advance COVID-19 vaccine strat…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

Scientists develop new biomimetic formulation for …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore ...

New needle-free nasal vaccine shows promise for CO…

New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mB...